Status:
RECRUITING
Randomized Withdrawal Study in Patients With Schizophrenia
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia...
Eligibility Criteria
Inclusion
- Males or females 18 to 65 years of age (inclusive)
- Diagnosed with schizophrenia per DSM-5 criteria
- In need of ongoing psychiatric treatment
Exclusion
- DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the primary focus of treatment within the previous six months
Key Trial Info
Start Date :
May 14 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2027
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06961968
Start Date
May 14 2025
End Date
November 1 2027
Last Update
September 12 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
San Diego, California, United States, 92102
2
Vanda Investigational Site
Richardson, Texas, United States, 75080